Servier and Oncodesign have selected a LRRK2 inhibitor as their partnership program’s lead candidate for Parkinson’s disease and…
Articles by Margarida Maia, PhD
Caraway Therapeutics is partnering with AbbVie to develop and market Caraway’s small molecule therapies targeting TMEM175, a potassium…
A considerable number of people with Parkinson’s disease living at home missed every flu vaccination given over five years…
A four-ingredient, small-molecule cocktail was seen to protect stem cells from the stresses of lab work better than existing agents,…
Parkinson’s disease does not appear to make a person more susceptible to infection with the COVID-19-causing virus, or at…
Men who experience sleepwalking — alone or in combination with another sleep disorder called rapid eye movement (REM) sleep behavior…